Imjudo (tremelimumab-actl) — Medica

Initial criteria

• age ≥ 18 years
• recurrent, advanced, or metastatic disease
• used in combination with Imfinzi (durvalumab intravenous infusion)
• meets one of the following: (a) tumor negative for actionable molecular markers and used as first-line therapy; OR (b) tumor positive for EGFR exon 20 mutation or ERBB2 (HER2) mutation and used as first-line therapy; OR (c) tumor positive for BRAF V600E mutation, NTRK1/2/3 gene fusion, MET exon 14 skipping mutation, or RET rearrangement and used as first-line or subsequent therapy; OR (d) tumor positive for EGFR exon 19 deletion, exon 21 L858R mutation, S768I, L861Q, and/or G719X mutation, ALK rearrangement, or ROS1 rearrangement, patient has received targeted drug therapy for the mutation, and used as subsequent therapy
• prescribed by or in consultation with an oncologist

Approval duration

6 months